Published in Clin Infect Dis on April 01, 1998
A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc Natl Acad Sci U S A (2002) 5.70
Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis (2001) 4.50
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax (2001) 3.38
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health (2000) 2.57
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother (2000) 2.22
Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev (1998) 2.13
Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother (1999) 2.02
Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis (2006) 1.92
Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One (2013) 1.84
Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla(TEM) genes. Antimicrob Agents Chemother (2000) 1.83
Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis (2007) 1.66
Using medical language processing to support real-time evaluation of pneumonia guidelines. Proc AMIA Symp (2000) 1.64
Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother (2003) 1.62
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother (2003) 1.57
Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.52
Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med (2002) 1.47
Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan. J Clin Microbiol (1999) 1.44
Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol (2005) 1.41
Current and emerging Legionella diagnostics for laboratory and outbreak investigations. Clin Microbiol Rev (2015) 1.41
Bench-to-bedside review: outcome predictions for critically ill patients in the emergency department. Crit Care (2005) 1.39
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.34
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.26
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother (2003) 1.16
Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother (2011) 1.12
Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis (2011) 1.11
Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob Agents Chemother (2003) 1.08
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.08
Physician awareness and self-reported use of local and national guidelines for community-acquired pneumonia. J Gen Intern Med (2003) 1.08
Clonal groups of penicillin-nonsusceptible Streptococcus pneumoniae in Baltimore, Maryland: a population-based, molecular epidemiologic study. J Clin Microbiol (2000) 1.04
Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob Agents Chemother (2001) 1.02
Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerg Infect Dis (2001) 1.01
Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor. Protein Sci (2008) 1.00
Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. CMAJ (2000) 1.00
What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med (2001) 0.98
In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother (2001) 0.98
Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis (2008) 0.97
Sampling variability in the microbiological evaluation of expectorated sputa and endotracheal aspirates. J Clin Microbiol (2001) 0.95
Increasing prevalence of vancomycin-resistant Enterococcus faecium, expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae, and imipenem-resistant Pseudomonas aeruginosa in Korea: KONSAR study in 2001. J Korean Med Sci (2004) 0.95
Exploring patient- and doctor-related variables associated with antibiotic prescribing for respiratory infections in primary care. Eur J Clin Pharmacol (2003) 0.95
Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother (2000) 0.94
Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother (2002) 0.93
Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program. Emerg Infect Dis (2015) 0.89
Usefulness of Gram stain for diagnosis of lower respiratory tract infection or urinary tract infection and as an aid in guiding treatment. Eur J Clin Microbiol Infect Dis (2003) 0.89
Use of an oxacillin disk screening test for detection of penicillin- and ceftriaxone-resistant pneumococci. J Clin Microbiol (1999) 0.89
Determinants for hospitalization in " low-risk" community acquired pneumonia. BMC Infect Dis (2003) 0.88
In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother (2003) 0.88
In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. Antimicrob Agents Chemother (2003) 0.87
Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae. Antimicrob Agents Chemother (2002) 0.86
Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. Emerg Med J (2003) 0.86
Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother (1999) 0.85
Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis (2009) 0.85
Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. Antimicrob Agents Chemother (2006) 0.84
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrob Agents Chemother (2003) 0.84
In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Antimicrob Agents Chemother (2006) 0.82
The new fluoroquinolones: A critical review. Can J Infect Dis (1999) 0.82
Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother (2003) 0.82
Role of non-conventional T lymphocytes in respiratory infections: the case of the pneumococcus. PLoS Pathog (2014) 0.81
Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures? World J Emerg Med (2011) 0.81
Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis (2000) 0.81
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother (2000) 0.81
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother (2000) 0.81
A new category--healthcare-associated pneumonia: a good idea, but problems with its execution. Eur J Clin Microbiol Infect Dis (2006) 0.81
Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob Agents Chemother (2001) 0.81
Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrob Agents Chemother (1999) 0.80
Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections. Curr Infect Dis Rep (2000) 0.80
Rehabilitation and Recovery After Stroke. Curr Treat Options Neurol (2000) 0.80
The utility of blood culture in patients with community-acquired pneumonia. Ochsner J (2001) 0.79
Anaerobic Infections of the Lung. Curr Infect Dis Rep (2000) 0.79
Pneumococcal Pneumonia. Curr Infect Dis Rep (1999) 0.79
Etiology and Anti-microbial Sensitivity of Organisms Causing Community Acquired Pneumonia: A Single Hospital Study. J Family Med Prim Care (2013) 0.79
New Fluoroquinolones: Real and Potential Roles. Curr Infect Dis Rep (1999) 0.79
Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. Antimicrob Agents Chemother (2009) 0.79
Approaches for guideline versioning using GLIF. AMIA Annu Symp Proc (2003) 0.79
Impact of positive legionella urinary antigen test on patient management and improvement of antibiotic use. J Clin Pathol (2004) 0.78
Improvement in process of care and outcome in patients requiring intensive care unit admission for community acquired pneumonia. BMC Infect Dis (2013) 0.77
Non-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity? Multidiscip Respir Med (2012) 0.77
Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. Ann Clin Microbiol Antimicrob (2007) 0.77
Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China. Antimicrob Agents Chemother (2004) 0.77
Aerosolization of respirable droplets from a domestic spa pool and the use of MS-2 coliphage and Pseudomonas aeruginosa as markers for Legionella pneumophila. Appl Environ Microbiol (2014) 0.77
The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax (2000) 0.76
Gram-Positive Pneumonia. Curr Infect Dis Rep (2000) 0.76
Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes. Can J Infect Dis Med Microbiol (2013) 0.76
Overview of lower respiratory tract infections: diagnosis and treatment. Ochsner J (2002) 0.76
Guidelinitis: A new syndrome? Can J Infect Dis (2000) 0.76
Outbreak of Pneumococcal Pneumonia among Military Recruits. Med J Armed Forces India (2011) 0.75
It's time to step up the management of community-acquired pneumonia. J Natl Med Assoc (2002) 0.75
Quinolones: which generation for which microbe? West J Med (1999) 0.75
Antibiotic prescribing: can we make it easier? J Gen Intern Med (2002) 0.75
Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia. Antimicrob Agents Chemother (2000) 0.75
Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother (1999) 0.75
A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group. Antimicrob Agents Chemother (2000) 0.75
Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. Antimicrob Agents Chemother (2009) 0.75
Diagnostic usefulness of ribosomal protein l7/l12 for pneumococcal pneumonia in a mouse model. J Clin Microbiol (2012) 0.75
Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumonia. HIV Med (2015) 0.75
Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ. Antimicrob Agents Chemother (2005) 0.75
[Community-acquired and nosocomial pneumonia]. Internist (Berl) (2003) 0.75
Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening. J Mol Model (2010) 0.75
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections. Wien Med Wochenschr (2003) 0.75
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med (1995) 5.18
Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med (1997) 4.84
Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med (2000) 4.20
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA (2000) 3.42
Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med (1992) 3.39
Changing epidemiology of group A streptococcal infection in the USA. Lancet (1990) 3.35
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA (1993) 3.31
The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis (1996) 3.26
The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis (1992) 3.04
Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med (1994) 2.70
Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis (1996) 2.55
Risk factors for transmission of Mycobacterium tuberculosis in a primary school outbreak: lack of racial difference in susceptibility to infection. Am J Epidemiol (1994) 2.34
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother (2000) 2.22
Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr (1996) 2.17
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Methicillin-resistant staphylococcus aureus and community-acquired pneumonia: an evolving relationship. Clin Infect Dis (2012) 1.97
Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J (1993) 1.95
Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis (1995) 1.93
Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin Infect Dis (1995) 1.91
Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol (1999) 1.91
Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife. Epidemiol Infect (2007) 1.87
Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet (1983) 1.80
Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. JAMA (1996) 1.79
An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med (1994) 1.73
Evidence against person-to-person transmission of hantavirus to health care workers. Clin Infect Dis (1996) 1.50
The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest (2000) 1.49
Aflatoxin levels in locally grown maize from Makueni District, Kenya. East Afr Med J (2008) 1.48
Risk factors for Nipah virus encephalitis in Bangladesh. Emerg Infect Dis (2008) 1.45
Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol (1998) 1.43
Rift Valley fever in Kenya: history of epizootics and identification of vulnerable districts. Epidemiol Infect (2010) 1.41
Comparison of Legionella pneumophila isolates by arbitrarily primed PCR and pulsed-field gel electrophoresis: analysis from seven epidemic investigations. J Clin Microbiol (1995) 1.40
Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Clin Infect Dis (1997) 1.40
Update in infectious diseases. Ann Intern Med (1997) 1.39
Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group. Arch Intern Med (1996) 1.39
Prevalence of sputum smear-positive tuberculosis in a rural area in Bangladesh. Epidemiol Infect (2006) 1.37
Community outbreak of Legionnaires' disease: an investigation confirming the potential for cooling towers to transmit Legionella species. Clin Infect Dis (1996) 1.36
High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr Infect Dis J (1995) 1.34
Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation. MMWR Recomm Rep (2000) 1.34
Comparison of Binax Legionella Urinary Antigen EIA kit with Binax RIA Urinary Antigen kit for detection of Legionella pneumophila serogroup 1 antigen. J Clin Microbiol (1996) 1.32
Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA (1996) 1.26
Advances in the epidemiology and control of Legionella infections. Epidemiol Rev (1991) 1.23
Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine (2009) 1.22
Use of multiple molecular subtyping techniques to investigate a Legionnaires' disease outbreak due to identical strains at two tourist lodges. J Clin Microbiol (1993) 1.21
Communitywide outbreak of Legionnaires' disease associated with a grocery store mist machine. J Infect Dis (1992) 1.21
More than 10 years of unrecognized nosocomial transmission of legionnaires' disease among transplant patients. Infect Control Hosp Epidemiol (1998) 1.20
Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients. J Infect Dis (1978) 1.19
Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis (2000) 1.18
Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis (1999) 1.16
Tuberculosis risk among staff of a large public hospital in Kenya. Int J Tuberc Lung Dis (2008) 1.11
Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia. J Infect Dis (1995) 1.08
Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infections. Antimicrob Agents Chemother (1984) 1.08
Incubation of water samples containing amoebae improves detection of legionellae by the culture method. Appl Environ Microbiol (1992) 1.07
A live avirulent mutant Legionella pneumophila vaccine induces protective immunity against lethal aerosol challenge. J Clin Invest (1989) 1.07
Effects of antimicrobial and antineoplastic drugs on the phagocytic and microbicidal function of the polymorphonuclear leukocyte. Rev Infect Dis (1982) 1.06
Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis (2004) 1.06
Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.06
Evaluation of the magnitude of the 1993 hantavirus outbreak in the southwestern United States. J Infect Dis (1995) 1.05
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother (1996) 1.04
Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections. Rev Infect Dis (1985) 1.04
Pneumococcal vaccine--past, present, and future. N Engl J Med (1991) 1.03
Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis (1996) 1.02
A community outbreak of Legionnaires' disease linked to hospital cooling towers: an epidemiological method to calculate dose of exposure. Int J Epidemiol (1999) 1.02
What are the most sensitive and specific sign and symptom combinations for influenza in patients hospitalized with acute respiratory illness? Results from western Kenya, January 2007-July 2010. Epidemiol Infect (2012) 1.01
Risk factors for typhoid fever in a slum in Dhaka, Bangladesh. Epidemiol Infect (2006) 1.00
Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis (2001) 1.00
The chemoprophylaxis of infection. A brief review of recent studies. Med Clin North Am (1978) 1.00
Nosocomial Legionnaires' disease and use of medication nebulizers. J Infect Dis (1991) 1.00
Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med (1994) 1.00
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. Antimicrob Agents Chemother (2004) 0.99
Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin Infect Dis (2000) 0.98
Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report. Can J Infect Dis (1993) 0.97
Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon-Kuskokwim Delta region of Alaska. Pediatr Infect Dis J (1996) 0.97
Intussusception, infection, and immunization: summary of a workshop on rotavirus. Pediatrics (2001) 0.96
High-pressure liquid chromatographic method for analysis of cephalosporins. Antimicrob Agents Chemother (1984) 0.96
Guideline for prevention of nosocomial pneumonia. The Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Infect Control Hosp Epidemiol (1994) 0.96
Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med (2000) 0.96
Outbreak of Legionnaires' disease associated with a display whirlpool spa. Int J Epidemiol (2000) 0.95
Comparison of a pneumococcal common protein (PsaA) antibody ELISA and a PsaA immune complex ELISA for detection of pneumococcal serum antibody. Pathobiology (1998) 0.95
Evidence against infection with hantaviruses among forest and park workers in the southwestern United States. Clin Infect Dis (1996) 0.95
Outbreak of pneumonia in a long-term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J Am Geriatr Soc (1998) 0.94
Effect of acidified enteral feedings on gastric colonization in the critically ill patient. Crit Care Med (1992) 0.94
A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia. J Antimicrob Chemother (1983) 0.94
In vitro susceptibility of the Bacteroides fragilis group in community hospitals. Diagn Microbiol Infect Dis (1986) 0.93
Diffusibility of the newer cephalosporins into human interstitial fluids. Am J Med (1984) 0.92
Cryptococcal meningitis in renal transplant patients associated with environmental exposure. Transpl Infect Dis (1999) 0.92
Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine (1998) 0.92